ライフサイエンスコーパス: tumor gene

1 s, which are specific mutations in the Wilms tumor gene.

2 the product of the lethal(3)malignant brain tumor gene.

3 indicated that these sites may harbor Wilms tumor genes.

4 identify novel activities for existing anti-tumor genes.

5 ty, and immunogenicity of a polyvalent Wilms tumor gene 1 (WT1) peptide vaccine in patients with acut

6 presses the transcriptional regulator Wilm's Tumor Gene 1 (Wt1).

7 emonstrate increased expression of the Wilms tumor gene 1 product (WT1), making WT1 an attractive the

8 Wilms tumor, and its product enhances Wilms tumor gene 1-mediated transcription.

9 e that PPP2R1A is not the 19q familial Wilms tumor gene and that mutation of PPP2R1A is not a common

10 wn to be overexpressed in AML such as Wilms' tumor gene, and multiparameter flow cytometry to detect

11 The OrCGDB is part of a larger WWW-based tumor gene database and represents a new approach to cat

12 structured digital publication software; the Tumor Gene Database, containing information about genes

13 to assess potential synergy of combined anti-tumor gene delivery and to identify novel activities for

14 One type of gene therapy of tumors, gene-directed enzyme-prodrug therapy (GDEPT), ho

15 iated with elevated expression of the Wilm's tumor gene encoded transcription factor (WT1).

16 Comparative tumor gene expression analysis revealed that several hum

17 ermine the relationship between quantitative tumor gene expression and risk of cancer recurrence in p

18 rofiling data to understand how TFs regulate tumor gene expression are still limited.

19 changes) alter tumor biology as assessed by tumor gene expression changes, with a common mechanism p

20 approach based upon statistical analysis of tumor gene expression data combined with experimental va

21 ncer cell lines and applying these models to tumor gene expression data in the clinical data sets (e.

22 Finally, we compared the murine lung tumor gene expression data to the expression of genes in

23 Integration of breast tumor gene expression data with the genes in the tumor s

24 e of absolute cell fraction predictions from tumor gene expression data, and provides a unique novel

25 lung cancer in a collection of 4,801 breast tumor gene expression data.

26 on of cancer and immune cell types from bulk tumor gene expression data.

27 This work demonstrates that tumor gene expression databases can be used to study the

28 Based on human tumor gene expression databases, HMGB1 was significantly

29 rrying out a meta-analysis of primary breast tumor gene expression from 1,378 early-stage breast canc

30 Our predicted TF impact on tumor gene expression is highly consistent with the know

31 In this study, tumor gene expression microarray profiles from pediatric

32 tability leading to mammary tumors that have tumor gene expression profiles closely resembling mature

33 be coexpressed with VEGFR-2 from a clinical tumor gene expression profiling database and between tum

34 Tumor gene expression profiling-targeted next-generation

35 However, this bias does not affect tumor gene expression profiling.

36 Accordingly, tumor gene expression signatures specific for myeloid ce

37 ides an exciting new technology for relating tumor gene expression to patient outcome, but it also pr

38 possibility of pharmacologically modulating tumor gene expression to result in targeted radiotherapy

39 r predicts subtype and patient survival than tumor gene expression, and genes with coordinated expres

40 l loci methylation inversely correlated with tumor gene expression, most notably KCNH2 (HERG, a potas

41 Entropy has been associated with tumor gene expression, tumor metabolism, tumor stage, pa

42 accounted for 1.2% of the total variation of tumor gene expression, while somatic copy-number alterat

43 o integrated RNA-Seq data in various primary tumors, gene expression microarray data in over 1000 can

44 d constitutional epigenetic defects in Wilms tumor genes extend the understanding of Wilms tumor risk

45 cer-related, with 95 colon tumor and 67 lung tumor genes identified, respectively.

46 ighly similar between responding ILC and IDC tumors; genes involved in proliferation were downregulat

47 The ovarian tumor gene is required during both early and late stages

48 ered and one of the most prevalently mutated tumor genes is Ras.

49 With the decreasing cost of tumor gene mutation testing and the increasing number of

50 The Drosophila ovarian tumor gene (otu) encodes cytoplasmic proteins that are r

51 the negative regulatory domain of the Wilms' tumor gene product (WT1) in a yeast two-hybrid screen an

52 In this study, we report that the Wilms' tumor gene product WT1, a zinc finger transcription fact

53 the adenovirus E1B-19K protein and the Wilms tumor gene product WT1.

54 Oncotype DX (ODX) is a tumor gene-profiling test that aids in adjuvant chemothe

55 operties of siRNA-L2 facilitated significant tumor gene silencing for 7 d after two i.v. doses.

56 krz(1) is a type 1 melanotic tumor gene; the fat body is the primary site of melanoti

57 ese findings have important implications for tumor gene therapy and for understanding the mechanism o

58 Clinical applications of tumor gene therapy require tumor-specific delivery or ex

59 , the vector being used in the ongoing brain tumor gene therapy trial.

60 nical applications in humans, especially for tumor gene therapy.

61 application for hematopoietic stem cell and tumor gene therapy.

62 tic interactions between cut and the ovarian tumor gene were identified as a result of the screen.

63 elopment requires the functions of the Wilms tumor gene WT1 and the WNT/beta-catenin signaling pathwa

64 The Wilms tumor gene WT1 encodes a zinc finger transcription facto

65 The tissue-specific Wilms' tumor gene WT1 is expressed in a range of acute leukemia

66 view recent findings showing that the Wilms' tumor gene (Wt1) is a key regulator of mesenchyme mainte

67 The Wilms' tumor gene (WT1) is an essential gene for kidney and gon

68 ostate cancer epithelial cells was the Wilms tumor gene (WT1).

69 The Wilms' tumor gene, WT1, encodes a zinc finger transcription fac

70 ed targets and regulators of the first Wilms tumor gene, WT1, has uncovered several candidate genes a

71 The product of the Wilms' tumor gene, WT1, is essential for male sex determination

72 One Wilms tumor gene, WT1, which encodes a zinc finger transcripti